- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678040
Ventricular Volume as Assessed by Cardiac Magnetic Resonance
July 9, 2019 updated by: Lars Grosse-Wortmann, The Hospital for Sick Children
MRI Assessment of the Effect of Preload on Ventricular Volumes and Function in Healthy Adult Volunteers
One of the many uses of cardiac magnetic resonance (CMR) is the assessment of right ventricular (RV) volumes.
There are a number of congenital heart defects and acquired conditions in which management decisions are fundamentally based on ventricular volumes.
The "gold standard" for assessment of RV volume is CMR.
It has better near-field resolution than echo and excellent contrast between the blood pool and the myocardium.
CMR is more suitable to the irregular geometry of the RV.
The objectives of this study are (1) to assess ventricular volumes in the fasting state and after oral hydration in order to assess the effect of fluid status on ventricular volumes as measured by CMR; (2) to evaluate the effect of hydration on ventricular volumes compared the effect of with inter-observer and intra-observer variability, and; (3) to evaluate the effects of chamber volume on chamber deformation, including strain and peak strain rate.
This study hypothesizes that (1) hydration status has an effect on right and left heart volumes, measured by CMR in healthy volunteers; (2) the effect of volume status will be a more significant contributor to variability in RV volumetry than that of inter-observer variability and intra-observer variability, and; (3) atrial and Ventricular deformation corrected for chamber size or volume is more accurate than when uncorrected for volume.
Study Overview
Status
Completed
Detailed Description
- To assess ventricular volumes in the fasting state and after oral hydration in order to assess the effect of fluid status on ventricular volumes as measured by CMR.
- To evaluate the effect of hydration on ventricular volumes compared the effect of with inter-observer and intra-observer variability.
- To evaluate the effects of chamber volume on chamber deformation, including strain and peak strain rate.
Study Type
Observational
Enrollment (Actual)
15
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Staff from the Heart Centre at The Hospital for Sick Children will be sent an email notifying them of the study.
They will be invited to obtain the particulars of the study by replying to Dr. Daryl Schantz or Dr. Lars Grosse-Wortmann.
If they agree to participate Dr. Schantz will obtain written informed consent.
Description
Inclusion Criteria:
- Participant must be healthy
Exclusion Criteria:
- Individuals who are unable to participate in an overnight fast will be excluded
- Those with known or suspected structural heart disease will be excluded
- A screening form to identify pre-existing cardiac conditions will be completed by the subject prior to participation in this study. If a pre-existing condition cardiac condition is identified, or suspected they will be excluded from the study.
- If any functional abnormality is detected at any stage by echocardiography or by CMR the study will be terminated. Common anatomical variants, which are generally regarded as normal variants (such as a patent foramen ovale, or a persistent left superior vena cava) will not lead to exclusion from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cardiac Magnetic Resonance
The CMR examinations will be performed in the cardiac MRI scanner (Siemens "Avanto", 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children.
A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fluid Status
Time Frame: Day 1
|
To assess ventricular volumes in the fasting state and after oral hydration in order to assess the effect of fluid status on ventricular volumes as measured by CMR.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hydration
Time Frame: Day 1
|
To evaluate the effect of hydration on ventricular volumes compared the effect of with inter-observer and intra-observer variability.
|
Day 1
|
|
Chamber Deformation
Time Frame: Day 1
|
To evaluate the effects of chamber volume on chamber deformation, including strain and peak strain rate
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lars Grosse-Wortmann, MD, The Hospital for Sick Children
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
August 30, 2012
First Submitted That Met QC Criteria
August 30, 2012
First Posted (Estimate)
September 3, 2012
Study Record Updates
Last Update Posted (Actual)
July 11, 2019
Last Update Submitted That Met QC Criteria
July 9, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- 1000031585
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmogenic Right Ventricular Cardiomyophathy (ARVC)
-
Lawson Health Research InstituteAbbott Medical DevicesTerminatedArrhythmogenic Right Ventricular Cardiomyopathy (ARVC)Canada
-
Implicit BioscienceCompletedArrhythmogenic Right Ventricular Dysplasia | Arrhythmogenic Right Ventricular Cardiomyopathy 1 | Arrhythmogenic Left Ventricular Cardiomyopathy | Arrhythmogenic Cardiomyopathy | ACM | ARVC | PKP2United States
-
University of Campania "Luigi Vanvitelli"CompletedRight Ventricle Abnormality
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Enrolling by invitationSudden Cardiac Arrest | Hypertrophic Cardiomyopathy (HCM) | Sudden Arrhythmic Death Syndrome | Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | Long QT Syndrome (LQTS) | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Canada
-
National Institutes of Health Clinical Center (CC)CompletedArrhythmic Right Ventricular CardiomyopathyUnited States
-
Istanbul University - CerrahpasaRecruitingArrhythmogenic Right Ventricular Cardiomyopathy | Cardiac Magnetic Resonance Imaging | FAPI PETTurkey (Türkiye)
-
Tenaya TherapeuticsMedical University of South Carolina; Johns Hopkins University; University of... and other collaboratorsRecruitingArrhythmogenic Right Ventricular CardiomyopathyUnited States, France, Italy, United Kingdom, Germany, Sweden
-
Rennes University HospitalRecruitingArrhythmogenic Right Ventricular CardiomyopathyFrance
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Boston Scientific Corporation; Medtroni... and other collaboratorsCompletedArrhythmogenic Right Ventricular CardiomyopathyCanada
-
Sheri Kashmir Institute of Medical SciencesUniversity of Pennsylvania; Indian Heart Rhythm Society; Sri Jayadeva Institute...Active, not recruitingVentricular Tachycardia | Sudden Cardiac Death | Arrhythmogenic Right Ventricular Cardiomyopathy | Arrhythmogenic Right Ventricular Dysplasia | Arrhythmogenic Ventricular Cardiomyopathy | Arrhythmogenic CardiomyopathyUnited States, India